{{Rsnum
|rsid=28647808
|Gene=ADAMTS13
|Chromosome=9
|position=133440409
|Orientation=plus
|GMAF=0.04408
|Gene_s=ADAMTS13
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}[[rs28647808]], also known as Pro618Ala, is a SNP in the [[ADAMTS13]] gene on chromosome 9, encoding a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13. The more common (C) allele encodes the Pro; the rarer (G) allele encodes the Ala. Serum ADAMTS13 activity was significantly lower in 618Ala carriers than in Pro/Pro homozygotes.

A study of 1,163 patients with [[type-2 diabetes]] was conducted to determine if this SNP led to higher renal or cardiavascular complications, and whether it played a role in the therapies designed to minimize these complications. Patients were randomized to ACE inhibition therapy or placebo, and then their reno- and/or cardio-complications were measured. The outcome was clear, at least in this one study: [[type-2 diabetes]] 618Ala carriers (i.e. [[rs28647808]](G) carriers) left untreated had about a 50% higher risk for renal complications (i.e. progression to microalbuminuria) compared to Pro/Pro homozygotes, but, they also responded twice as well to ACE inhibitor therapy (i.e. in terms of progression to the renal end-point, ~3% vs ~6% for the Pro/Pro patients treated by ACEi).{{PMID|23733198}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}